TY  - JOUR
AU  - Landry, Alexander P
AU  - Wang, Justin Z
AU  - Patil, Vikas
AU  - Liu, Jeff
AU  - Gui, Chloe
AU  - Ellenbogen, Yosef
AU  - Ajisebutu, Andrew
AU  - Yefet, Leeor
AU  - Wei, Qingxia
AU  - Singh, Olivia
AU  - Sosa, Julio
AU  - Mansouri, Sheila
AU  - Cohen-Gadol, Aaron A
AU  - Tabatabai, Ghazaleh
AU  - Tatagiba, Marcos
AU  - Behling, Felix
AU  - Barnholtz-Sloan, Jill S
AU  - Sloan, Andrew E
AU  - Chotai, Silky
AU  - Chambless, Lola B
AU  - Mansouri, Alireza
AU  - Makarenko, Serge
AU  - Yip, Stephen
AU  - Ehret, Felix
AU  - Capper, David
AU  - Tsang, Derek S
AU  - Moliterno, Jennifer
AU  - Gunel, Murat
AU  - Wesseling, Pieter
AU  - Sahm, Felix
AU  - Aldape, Kenneth
AU  - Gao, Andrew
AU  - Zadeh, Gelareh
AU  - Nassiri, Farshad
TI  - Chromosome 1p Loss and 1q Gain for Grading of Meningioma.
JO  - JAMA oncology
VL  - 11
IS  - 6
SN  - 2374-2437
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DKFZ-2025-00715
SP  - 644-649
PY  - 2025
N1  - 2025 Jun 1;11(6):644-649
AB  - The World Health Organization (WHO) classification of central nervous system tumors (CNS) grading for meningioma was updated in 2021 to include rare molecular features, namely homozygous deletions of CDKN2A or CDKN2B and TERT promotor alterations. Previous work, including the cIMPACT-NOW statement, has discussed the potential value of including chromosomal copy number alterations to help refine the current grading system.To identify chromosomal copy number alterations that could be used to improve the current CNS WHO grading of meningioma.In this cohort study, patients with surgically treated meningioma were followed-up until recurrence or progression of disease or death. Chromosomal copy number alterations were then correlated with progression-free survival (PFS) to identify new outcome biomarkers. This study included patients with a histopathological diagnosis of meningioma from multiple institutions in Canada, the US, and Germany, with molecular data collection starting in 2016. Data were analyzed from January to September 2024.All patients underwent surgery for meningioma and a subset underwent radiation therapy.The main outcome was PFS. Cox regression analysis was used to identify copy number alterations associated with outcomes in the context of WHO grading.Among 1964 patients with meningioma (1256 female; median [IQR] age, 58 [48-69] years) assessed, loss of chromosome 1p in WHO grade 1 meningiomas was associated with significantly worse outcomes compared with tumors without loss of 1p (median PFS, 5.83 [95
LB  - PUB:(DE-HGF)16
C6  - pmid:40178835
DO  - DOI:DOI:10.1001/jamaoncol.2025.0329
UR  - https://inrepo02.dkfz.de/record/300254
ER  -